Caplacizumab Biosimilar - Research Grade

Human

VWF

>1mg/ml

Human Fc

https://www.imgt.org/mAb-DB/

ICH3002

P04275

Blue ice

This is an unconjugated, non-therapeutic recombinant research analog of caplacizumab, an anti-von Willebrand Factor (VWF) binder directed at the VWF A1 domain, supplied for research use only. It is not the clinical drug and is not intended for human or veterinary use. The analog is built around the same molecular target as the originator, making it useful as a reference binder for in-vitro and preclinical studies of VWF-platelet interactions, as an assay control or standard, and as a tool for developing and validating VWF-directed detection or neutralization assays. It is offered in bulk milligram-to-gram quantities and as low-endotoxin material (research grade <1 EU/mg; ultra-low <0.5 EU/mg) suitable for cell-based and in-vivo-standard applications where endotoxin must be controlled. Typical research applications include target-binding characterization, epitope/competition studies, blockade of VWF A1-GPIb-dependent platelet adhesion under shear in flow-chamber models, positive/negative controls in ELISA and surface-based binding assays, and biosimilar comparability work. Reviewers should confirm format details against their intended workflow before use. Von Willebrand Factor (VWF; UniProt P04275) is a large multimeric plasma glycoprotein made by endothelial cells and megakaryocytes and stored in Weibel-Palade bodies and platelet alpha-granules. It mediates primary hemostasis by tethering platelets to exposed subendothelial collagen at sites of vascular injury, especially under high shear. The VWF A1 domain binds platelet glycoprotein Ib-alpha (GPIbalpha), the A3 domain binds collagen, and the D'D3 region binds and stabilizes coagulation factor VIII. Ultra-large VWF multimers are normally cleaved by the metalloprotease ADAMTS13; when ADAMTS13 activity is deficient, hyperadhesive multimers persist and drive microvascular platelet aggregation, as in thrombotic thrombocytopenic purpura (TTP). Qualitative or quantitative VWF defects instead cause von Willebrand disease. Blocking the A1-GPIbalpha interaction prevents shear-dependent platelet recruitment.

von Willebrand factor, F8VWF

Detects human VWF. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Caplacizumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.